

## PRESS RELEASE

**Oberdorf, March 31st 2021**

### **Unicyte AG welcomes Dr. Frank Weber as Chief Medical Officer**

Unicyte AG, a regenerative medicine company developing stem cell and nano-Extracellular Vesicle-based therapies, is pleased to announce the appointment of Dr. Frank Weber as its Chief Medical Officer. Frank Weber started working with Unicyte AG as a Medical Advisor about two years ago and significantly contributed to the development of the company and their assets.

“Frank is an outstanding addition to the team and brings a wealth of experience as a CMO and leader in both, large pharma as well as biotech companies, and he has a strong track record in driving clinical development programs” said Florian Jehle, CEO Unicyte AG.

In his role, Dr. Weber will support Unicyte in guiding the clinical development program including regulatory strategy serving as the clinical lead for the company, also managing interfaces with key opinion leaders.

Dr. Weber graduated at the University Cologne, Germany and spent 10 years in academic research and clinical practice in immunology, infectiology and maxillofacial surgery at the University Hospital of Cologne. During more than 25 years in the pharmaceutical industry, he held Chief Medical Officer and Executive Management positions in international pharmaceutical companies in Europe and the US. He contributed to multiple compounds moving from research to clinical proof of concept and from early development to market, and he was involved in major M&A and licensing deals.

"I am honored to be provided with the opportunity to work together with one of the leading research and management teams in the field of regenerative medicine. Based on more than 20 years of research under the leadership of Prof. Giovanni Camussi, the transition of stem cell and stem cell derived products into the clinical development proof of concept stage and further into fast to market programs will provide new opportunities to improve the health and wellbeing of patients with currently underserved severe and chronic disorders" said Frank Weber.

Unicyte AG is a regenerative medicine company with a focus on kidney & liver disorders, diabetes and oncology, headquartered in Oberdorf NW, Switzerland. Unicyte evolved from a long-term research collaboration of Italy's University of Turin and Fresenius Medical Care, and is an independent affiliate of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases. For more information visit [www.unicyte.ch](http://www.unicyte.ch).